Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Capital Expenditures (2016 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Capital Expenditures for 13 consecutive years, with $1000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Capital Expenditures fell 98.8% year-over-year to $1000.0, compared with a TTM value of $1000.0 through Jun 2024, down 99.75%, and an annual FY2023 reading of $197000.0, down 8.8% over the prior year.
  • Capital Expenditures was $1000.0 for Q3 2023 at Alaunos Therapeutics, down from $95000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $8.6 million in Q4 2020 and bottomed at -$2.8 million in Q3 2020.
  • Average Capital Expenditures over 5 years is $845250.0, with a median of $98000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures soared 5030.0% in 2020, then crashed 113.16% in 2021.
  • Year by year, Capital Expenditures stood at $10000.0 in 2019, then soared by 86050.0% to $8.6 million in 2020, then plummeted by 95.83% to $359000.0 in 2021, then crashed by 67.69% to $116000.0 in 2022, then tumbled by 99.14% to $1000.0 in 2023.
  • Business Quant data shows Capital Expenditures for TCRT at $1000.0 in Q3 2023, $95000.0 in Q2 2023, and $101000.0 in Q1 2023.